Treatment of insomnia with zaleplon, a novel sleep medication

International Journal of Clinical Practice

Volumn 55, Issue 5, 2001, Pages 329-334

  Doghramjl, P P ^a,b  

^a NONE

^b Brooklyn Family Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; CIMETIDINE; DIGOXIN; DIPHENHYDRAMINE; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; PAROXETINE; THIORIDAZINE; TRIAZOLAM; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG ELIMINATION; HUMAN; INSOMNIA; PRESCRIPTION; PREVALENCE; PREVENTION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REBOUND; RECEPTOR AFFINITY; RECEPTOR BINDING; RISK; SEDATION; SIDE EFFECT; SLEEP DISORDER; STANDARD; SYMPTOM; VERTIGO; WITHDRAWAL SYNDROME;

ACETAMIDES; AGED; CLINICAL TRIALS; HUMANS; HYPNOTICS AND SEDATIVES; PYRIMIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 0034960862     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Costa e Suva JA, Chase M, Sartorius N. Roth T. Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: an overview of insomnias and related disorders: recognition, epidemiology, and rational management. Sleep 1996; 19: 412-416.
2. Becker PM, Jamieson AO, Brown WD. Insomnia: use of a 'decision tree' to assess and treat. Postgrad Med 1993; 93: 66-80. 85.
3. Maczaj M. Pharmacological treatment of insomnia. Drugs 1993; 45: 44-55.
4. National Center on Sleep Disorders Research Working Group. Recognizing problem sleepiness in your patients. Am Fum Physician 1999; 59: 937-944.
5. Dement WC. The proper use of sleeping pills in the primary care setting. J din Psychiatry 1992; 53(12 suppl): 50-56.
6. Dietrich B, Emilien G, Saunas E. Zaleplon does not produce residual sedation in a phase-advance model of transient insomnia [abstract 133]. ] Sleep Res 1998; 7(suppl 2): 67.
7. Dämgen K, Lüddens H. Zaleplon displays a selectivity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Communications 1999; 25: 139-148.
8. Greenblatt DJ, Harmatz JS, von Moltke LL el til. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64: 553-561.
9. Wickland C, Patat A. Pharmacokinetics and safety of zaleplon in patients with renal failure [poster]. Presented at World Federation of Sleep Research Societies Third International Congress; October 1999; Dresden, Germany.
10. Darwish M. The effects of age and gender on the pharmacokinetics of Sonata-(zaleplon) [poster]. Presented at 12th European College of Neuropsychopharmacology; September 1999; London, England.
11. Wickland C, Patat A. Safety and pharmacokinetics of zaleplon in hepatically impaired patients [poster]. Presented at World Federation of Sleep Research Societies Third International Congress; October 1999; Dresden, Germany.
12. Darwish M. Overview of drug-interaction studies with zaleplon. Sleep 1999; 22(suppl 1): S280-S281.
13. Prescribing information: Sonata (zaleplon) capsules. Physicians' Desk Reference,54th edn. Montvale, NJ: Medical Economics Co 2000: 3319-3323.
14. Walsh JK, Vogel GW, Scharf M et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000; 1:41-49.
15. Cluydts R. A 28-night evaluation of the efficacy, next-day effects, and withdrawal potential of zaleplon and zolpidem in outpatients with primary insomnia. Postgraduate medicine - a special report. Insomnia: treatment options for the 2Ist century. Minneapolis: McGraw-Hill, 2000: 14-24.
16. Elie R, Riither E, Fair I et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999; 60: 536-544.
17. Hedner J, Yaeche R, Emilien G et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psychiatry 2000; 15: 704-712.
18. Erwin CW, Fry JM, Richardson GS et al. Zaleplon effectively and safely shortens sleep latency in elderly insomniacs [poster]. Presented at American Geriatrics Society (ACS) 1999 Annual Meeting; May 1999; Philadelphia, PA.
19. Ancoli-Israel S, Walsh JK, Mangano RM et al. Zaleplon, a novel non-benzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion to Journal of Clinical Psychiatry 1999; 1: 114-120.
20. Troy SM, Lucki I, Unruh MA et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. ] Clin Psychopharmacol 2000; 20: 328-337.
21. Danjou P. Paty I, Fruncillo R et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999; 48: 367-374.
22. Vermeeren A, Danjou PE.O'Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Human Psychopharmacol Clin Exper 1998; 13: S98-S107.
23. Scharf MB. Evaluation of next-day functioning and residual sedation in healthy subjects: zaleplon vs. flurazepam. Postgraduate medicine: a special report. Insomnia: treatment options for the 21st century. Minneapolis: McGraw-Hill,2000: 25-32.
24. Walsh JK, Pollak CP, Scharf MB et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000; 23: 17-21.
25. Scharf M. The safety of long-term treatment of insomnia with zaleplon [abstract]. Eur Neuropsychopharmacol 1999; 9(suppl 5): S360-S361.
26. Hedner J, Mangano R. Zaleplon provides safe long-term treatment of insomnia in the elderly [abstract P.6.048]. Eur Neuropsychopharmacol 1999;9(suppl5):S362.
27. Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990; 19: 53-61.
28. Walsh JK, Fry J, Erwin CW et al. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 1998; 16: 347-354.
29. Fry J, Scharf M, Mangano R et al. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 2000; 15: 141-152.
30. George CFP, Series F, Kryger MH, Moscovitch A. Safety and efficacy of zaleplon versus zolpidem in outpatients with chronic obstructive pulmonary disease (COPD) and insomnia [abstract C527.L]. Sleep 1999; 22(suppl 1): S320.